<p>NewEdge Advisors LLC 在最近向证券交易委员会提交的 13F 表格中披露，其在波士顿科学公司（纽约证券交易所代码：BSX - 免费报告）的股份在第二季度增加了 14.1%。该基金在此期间额外购买了 13,527 股后，持有该医疗设备提供商的 109,313 股。根据其最近向证券交易委员会的提交，NewEdge Advisors LLC 在波士顿科学的持股价值为 11,741,000 美元。</p>
<p>获取 <strong>波士顿科学</strong> 警报：</p>
<ul>
<li>注意死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
<p>其他几家机构投资者最近也买卖了该公司的股票。挪威银行在第二季度新建了波士顿科学的股份，价值 2,089,937,000 美元。Edgewood Management LLC 在第二季度新建了波士顿科学的股份，估计价值约为 746,655,000 美元。贝瑟默集团在第二季度将其在波士顿科学的股份提高了 14,391.8%。贝瑟默集团现在拥有 2,919,801 股该医疗设备提供商的股票，价值 313,618,000 美元，此前在上个季度额外购买了 2,899,653 股。先锋集团在第二季度将其在波士顿科学的持股增加了 1.9%。先锋集团现在拥有 137,134,110 股该医疗设备提供商的股票，价值 14,729,575,000 美元，此前在上个季度额外购买了 2,545,381 股。最后，Price T Rowe Associates Inc. MD 在第一季度将其在波士顿科学的股份增加了 18.6%。Price T Rowe Associates Inc. MD 现在拥有 10,610,487 股该医疗设备提供商的股票，价值 1,070,387,000 美元，此前在上个季度额外购买了 1,664,108 股。目前，89.07% 的股票由机构投资者和对冲基金持有。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，董事 Ellen M. Zane 于 11 月 6 日星期四出售了 12,891 股公司的股票。股票以平均价格 98.28 美元出售，总交易额为 1,266,927.48 美元。出售后，该董事持有 24,134 股公司股票，价值 2,371,889.52 美元。这笔交易代表了其持股的 34.82% 的减少。该交易在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，执行副总裁 Arthur C. Butcher 于 12 月 1 日星期一出售了 17,313 股公司的股票。股票以平均价格 101.55 美元出售，总交易额为 1,758,135.15 美元。交易完成后，该执行副总裁持有 23,600 股公司的股票，价值约 2,396,580 美元。这代表了其持股的 42.32% 的减少。该销售的披露在 SEC 文件中可获得。在过去的 90 天里，内部人士已出售 143,095 股公司股票，价值 14,228,950 美元。公司内部人士持有 0.50% 的公司股票。</p>
<h2>波士顿科学价格表现</h2>
<ul>
<li>3 只利用人工智能推动增长的医疗股</li>
</ul>
<p>波士顿科学（NYSE:BSX）周五开盘价为 91.60 美元。该公司的 50 日移动平均线为 98.95 美元，200 日移动平均线为 101.73 美元。该公司的市值为 1357.9 亿美元，市盈率为 48.98，PEG 比率为 1.87，贝塔值为 0.67。该公司的债务与股本比率为 0.47，速动比率为 0.96，流动比率为 1.51。波士顿科学公司的 1 年低点为 85.98 美元，1 年高点为 109.50 美元。</p>
<p>波士顿科学（NYSE:BSX - 获取免费报告）最近于 10 月 22 日星期三发布了季度收益数据。该医疗设备提供商报告本季度每股收益（EPS）为 0.75 美元，超出市场共识预期的 0.71 美元，超出 0.04 美元。波士顿科学的股本回报率为 19.46%，净利润率为 14.43%。该公司本季度的收入为 50.7 亿美元，而分析师预期为 49.7 亿美元。在去年同期，该公司每股收益为 0.63 美元。该公司本季度的收入同比增长 20.3%。波士顿科学已将其 2025 财年的指引设定为每股收益 3.020-3.040 美元，2025 年第四季度的指引设定为每股收益 0.770-0.790 美元。研究分析师预计波士顿科学公司今年将发布 2.85 美元的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
<p>几位股票分析师最近对 BSX 股票发表了评论。瑞银集团将波士顿科学的股票目标价从 135.00 美元上调至 140.00 美元，并在 10 月 23 日星期四的研究报告中给予该公司 “买入” 评级。罗伯特·W·贝尔德将波士顿科学的股票目标价从 123.00 美元上调至 128.00 美元，并在 10 月 1 日星期三的研究报告中给予该股票 “跑赢大盘” 评级。加拿大皇家银行在 9 月 29 日星期一的报告中重申了 “跑赢大盘” 评级，并设定波士顿科学的股票目标价为 125.00 美元。Cowen 在研究报告中重申了波士顿科学的 “买入” 评级。最后，富国银行将波士顿科学的目标价从 124.00 美元上调至 125.00 美元，并在 10 月 23 日星期四的研究报告中给予该公司 “增持” 评级。两位研究分析师对该股票给予了强烈买入评级，二十一位给予了买入评级，二位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 124.43 美元。</p>
<p><strong>查看我们最新的波士顿科学股票分析</strong></p>
<h2>波士顿科学公司简介</h2>
<p>（免费报告）</p>
<p>波士顿科学公司开发、制造和销售用于全球各类介入医学专业的医疗设备。它通过两个部门运营，分别是医疗外科和心血管。该公司提供用于诊断和治疗胃肠和肺部疾病的设备，如解决夹、胆道支架系统、支架和电切增强输送系统、直接可视化系统、数字导管和一次性十二指肠镜；用于治疗泌尿系统疾病的设备，包括输尿管支架、导管、篮子、导丝、鞘、气囊、一次性数字柔性输尿管镜、霍尔米激光系统、人工尿道括约肌、激光系统、光纤和水凝胶系统；以及用于治疗神经运动障碍和管理慢性疼痛的设备，如脊髓刺激器系统、专有编程软件、射频发生器、间接减压系统、实践优化工具和深脑刺激系统。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过波士顿科学</li>
<li>3 只防御类股票将受益于军事支出增加</li>
<li>3 只最近被下调评级的股票，2026 年应避免</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>芯片热潮回归：3 只股票有望获得巨大收益</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>甲骨文股票遭重创：为何其人工智能管道可能推动 2026 年反弹</li>
</ul>
<p><strong>想看看其他对 BSX 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取波士顿科学公司（NYSE:BSX - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在波士顿科学吗？</h2>
<p>在考虑波士顿科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而波士顿科学并不在名单上。</p>
<p>虽然波士顿科学目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

波士顿科学

<p>NewEdge Advisors LLC 在第二季度将其在波士顿科学公司的股份增加了 14.1%，目前持有 109,313 股，价值 1174 万美元。其他主要投资者如挪威银行和先锋集团也调整了他们的持仓。内部人士最近出售了大量股份。波士顿科学的第三季度收益超出预期，年同比收入增长 20.3%。分析师们提高了价格目标，表明公司有积极的增长前景</p>

<p>NewEdge Advisors LLC boosted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 14.1% in the second quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 109,313 shares of the medical equipment provider's stock after acquiring an additional 13,527 shares during the period. NewEdge Advisors LLC's holdings in Boston Scientific were worth $11,741,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>NewEdge Advisors LLC 在最近向证券交易委员会提交的 13F 表格中披露，其在波士顿科学公司（纽约证券交易所代码：BSX - 免费报告）的股份在第二季度增加了 14.1%。该基金在此期间额外购买了 13,527 股后，持有该医疗设备提供商的 109,313 股。根据其最近向证券交易委员会的提交，NewEdge Advisors LLC 在波士顿科学的持股价值为 11,741,000 美元。</p>
</div><p>Get <strong>Boston Scientific</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>波士顿科学</strong> 警报：</p>
</div><ul>
<li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>注意死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
</div><p>Several other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Boston Scientific during the second quarter worth $2,089,937,000. Edgewood Management LLC acquired a new position in Boston Scientific during the 2nd quarter valued at about $746,655,000. Bessemer Group Inc. raised its stake in Boston Scientific by 14,391.8% in the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider's stock valued at $313,618,000 after buying an additional 2,899,653 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也买卖了该公司的股票。挪威银行在第二季度新建了波士顿科学的股份，价值 2,089,937,000 美元。Edgewood Management LLC 在第二季度新建了波士顿科学的股份，估计价值约为 746,655,000 美元。贝瑟默集团在第二季度将其在波士顿科学的股份提高了 14,391.8%。贝瑟默集团现在拥有 2,919,801 股该医疗设备提供商的股票，价值 313,618,000 美元，此前在上个季度额外购买了 2,899,653 股。先锋集团在第二季度将其在波士顿科学的持股增加了 1.9%。先锋集团现在拥有 137,134,110 股该医疗设备提供商的股票，价值 14,729,575,000 美元，此前在上个季度额外购买了 2,545,381 股。最后，Price T Rowe Associates Inc. MD 在第一季度将其在波士顿科学的股份增加了 18.6%。Price T Rowe Associates Inc. MD 现在拥有 10,610,487 股该医疗设备提供商的股票，价值 1,070,387,000 美元，此前在上个季度额外购买了 1,664,108 股。目前，89.07% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, Director Ellen M. Zane sold 12,891 shares of the firm's stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company's stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 143,095 shares of company stock worth $14,228,950. Corporate insiders own 0.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Ellen M. Zane 于 11 月 6 日星期四出售了 12,891 股公司的股票。股票以平均价格 98.28 美元出售，总交易额为 1,266,927.48 美元。出售后，该董事持有 24,134 股公司股票，价值 2,371,889.52 美元。这笔交易代表了其持股的 34.82% 的减少。该交易在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，执行副总裁 Arthur C. Butcher 于 12 月 1 日星期一出售了 17,313 股公司的股票。股票以平均价格 101.55 美元出售，总交易额为 1,758,135.15 美元。交易完成后，该执行副总裁持有 23,600 股公司的股票，价值约 2,396,580 美元。这代表了其持股的 42.32% 的减少。该销售的披露在 SEC 文件中可获得。在过去的 90 天里，内部人士已出售 143,095 股公司股票，价值 14,228,950 美元。公司内部人士持有 0.50% 的公司股票。</p>
</div><h2>Boston Scientific Price Performance</h2>
<div class="lb-trans"><h2>波士顿科学价格表现</h2>
</div><ul>
<li>3 Healthcare Stocks Using AI to Drive Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只利用人工智能推动增长的医疗股</li>
</ul>
</div><p>NYSE:BSX opened at $91.60 on Friday. The firm's fifty day moving average is $98.95 and its two-hundred day moving average is $101.73. The firm has a market cap of $135.79 billion, a price-to-earnings ratio of 48.98, a PEG ratio of 1.87 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50.</p>
<div class="lb-trans"><p>波士顿科学（NYSE:BSX）周五开盘价为 91.60 美元。该公司的 50 日移动平均线为 98.95 美元，200 日移动平均线为 101.73 美元。该公司的市值为 1357.9 亿美元，市盈率为 48.98，PEG 比率为 1.87，贝塔值为 0.67。该公司的债务与股本比率为 0.47，速动比率为 0.96，流动比率为 1.51。波士顿科学公司的 1 年低点为 85.98 美元，1 年高点为 109.50 美元。</p>
</div><p>Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analysts' expectations of $4.97 billion. During the same quarter in the previous year, the firm posted $0.63 EPS. The company's revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.</p>
<div class="lb-trans"><p>波士顿科学（NYSE:BSX - 获取免费报告）最近于 10 月 22 日星期三发布了季度收益数据。该医疗设备提供商报告本季度每股收益（EPS）为 0.75 美元，超出市场共识预期的 0.71 美元，超出 0.04 美元。波士顿科学的股本回报率为 19.46%，净利润率为 14.43%。该公司本季度的收入为 50.7 亿美元，而分析师预期为 49.7 亿美元。在去年同期，该公司每股收益为 0.63 美元。该公司本季度的收入同比增长 20.3%。波士顿科学已将其 2025 财年的指引设定为每股收益 3.020-3.040 美元，2025 年第四季度的指引设定为每股收益 0.770-0.790 美元。研究分析师预计波士顿科学公司今年将发布 2.85 美元的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 Biotech Catalysts Present Major Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
</div><p>Several equities analysts recently commented on BSX shares. UBS Group increased their price objective on shares of Boston Scientific from $135.00 to $140.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 23rd. Robert W. Baird lifted their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday, October 1st. Royal Bank Of Canada reissued an &#34;outperform&#34; rating and set a $125.00 price objective on shares of Boston Scientific in a report on Monday, September 29th. Cowen restated a &#34;buy&#34; rating on shares of Boston Scientific in a research note on Thursday. Finally, Wells Fargo &amp; Company boosted their price target on Boston Scientific from $124.00 to $125.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average price target of $124.43.</p>
<div class="lb-trans"><p>几位股票分析师最近对 BSX 股票发表了评论。瑞银集团将波士顿科学的股票目标价从 135.00 美元上调至 140.00 美元，并在 10 月 23 日星期四的研究报告中给予该公司 “买入” 评级。罗伯特·W·贝尔德将波士顿科学的股票目标价从 123.00 美元上调至 128.00 美元，并在 10 月 1 日星期三的研究报告中给予该股票 “跑赢大盘” 评级。加拿大皇家银行在 9 月 29 日星期一的报告中重申了 “跑赢大盘” 评级，并设定波士顿科学的股票目标价为 125.00 美元。Cowen 在研究报告中重申了波士顿科学的 “买入” 评级。最后，富国银行将波士顿科学的目标价从 124.00 美元上调至 125.00 美元，并在 10 月 23 日星期四的研究报告中给予该公司 “增持” 评级。两位研究分析师对该股票给予了强烈买入评级，二十一位给予了买入评级，二位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 124.43 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Boston Scientific</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的波士顿科学股票分析</strong></p>
</div><h2>Boston Scientific Company Profile</h2>
<div class="lb-trans"><h2>波士顿科学公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.</p>
<div class="lb-trans"><p>波士顿科学公司开发、制造和销售用于全球各类介入医学专业的医疗设备。它通过两个部门运营，分别是医疗外科和心血管。该公司提供用于诊断和治疗胃肠和肺部疾病的设备，如解决夹、胆道支架系统、支架和电切增强输送系统、直接可视化系统、数字导管和一次性十二指肠镜；用于治疗泌尿系统疾病的设备，包括输尿管支架、导管、篮子、导丝、鞘、气囊、一次性数字柔性输尿管镜、霍尔米激光系统、人工尿道括约肌、激光系统、光纤和水凝胶系统；以及用于治疗神经运动障碍和管理慢性疼痛的设备，如脊髓刺激器系统、专有编程软件、射频发生器、间接减压系统、实践优化工具和深脑刺激系统。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Boston Scientific</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过波士顿科学</li>
<li>3 只防御类股票将受益于军事支出增加</li>
<li>3 只最近被下调评级的股票，2026 年应避免</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>芯片热潮回归：3 只股票有望获得巨大收益</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>甲骨文股票遭重创：为何其人工智能管道可能推动 2026 年反弹</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BSX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 BSX 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取波士顿科学公司（NYSE:BSX - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在波士顿科学吗？</h2>
</div><p>Before you consider Boston Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑波士顿科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而波士顿科学并不在名单上。</p>
</div><p>While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然波士顿科学目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

NewEdge Advisors LLC 增加了其在波士顿科学公司 $BSX 的股票持仓